---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-019779"
form_type: "8-K"
ticker: "ADIL"
cik: "0001513525"
company_name: "ADIAL PHARMACEUTICALS, INC."
filed_at: "2025-03-04T23:59:59+00:00"
generated_at: "2026-05-25T13:50:33.265445+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Adial Pharma FY2024 net loss $13.2M, cash $3.8M; FDA confirms AD04 505(b)(2) path

## Summary
- Net loss $13.2M in FY2024 versus $5.1M in FY2023; widened primarily on $4.5M non-cash inducement charge.
- Cash and equivalents $3.8M at year-end; expects to fund operations into H2 2025.
- R&D spend rose $1.9M (+155%) driven by PK study and CMC manufacturing for AD04 Phase 3.
- FDA confirmed 505(b)(2) bridging strategy; Phase 3 trial to begin in 2025.
- Appointed Vinay Shah as CFO in November 2024; secured three new U.S. patents for AD04 genetic diagnostics.

## SEC filing metadata
- accession: 0001213900-25-019779
- form_type: 8-K
- ticker: ADIL
- cik: 0001513525
- company_name: ADIAL PHARMACEUTICALS, INC.
- filed_at: 2025-03-04T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1513525/000121390025019779/0001213900-25-019779-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1513525/000121390025019779/ea0232881-8k_adial.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-019779
- JSON: https://secwatch.observer/filing/0001213900-25-019779.json
- Plain text: https://secwatch.observer/filing/0001213900-25-019779.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.